Rasagiline has a neuroprotective effect on RGC survival in glaucomatous rats

Article

Rasagiline can be used as a systematic treatment to improve chances of retinal ganglion cell (RGC) survival in glaucomatous eyes

Rasagiline can be used as a systematic treatment to improve chances of retinal ganglion cell (RGC) survival in glaucomatous eyes, according to a study featured in the Journal of Glaucoma.

A team led by Dr Hani Levkovitch-Verbin, Goldschleger Eye Institute, Tel Hashomer, Israel, injected the anti-Parkison disease drug into Wistar rats. The rats were split into a 3mg/kg, 0.5 mg/kg group and a saline-treated group.

Intraocular pressure (IOP) was measured before and after the injections and weekly for seven weeks. All the rats were killed and their eyes were enucleated and the retinas were set up as whole mounts. Ten days before enucleation fluoro-gold was injected into the superior colliculus. To calulate RGC survival the remaining labelled RGCs were counted in a masked way.

All of the rats presented with a significantly higher IOP and RGC damage. The mean RGC survival rate was 43±8% in the rasagiline 3 mg/kg-treated group and 43±9% in the rasagiline 0.5 mg/kg-treated group. This was compared with 23%±4% in the saline-treated (control) group.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.